Fibrinogen Antigen, Plasma
Use
The test is used for the evaluation of fibrinogen deficiency, measuring fibrinogen in patients with elevated plasma levels of fibrin degradation products, patients receiving heparin, and in those with antibodies to thrombin following surgical use of topical bovine thrombin. It aids in identifying afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia, especially when ordered with fibrinogen activity (FIBTP / Fibrinogen, Plasma).
Special Instructions
Differentiation of congenital from acquired defects of fibrinogen requires clinical correlation with standard clotting-based fibrinogen activity testing (FIBTP / Fibrinogen, Plasma).
Limitations
Fibrinogen is an acute phase reactant; hence, plasma levels can be increased by inflammatory illnesses, nephrotic syndrome, liver disease, pregnancy, estrogen therapy, and compensated intravascular coagulation. Detection of congenital versus acquired fibrinogen defects relies on clinical correlation and other testing results. The test measures the antigenic presence of fibrinogen protein but not its functional activity, which might lead to misinterpretation in the presence of dysfibrinogenemia.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Immunoturbidimetric)
Biomarkers
LOINC Codes
- 3256-5
- 3256-5
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL
Minimum Volume
0.5 mL
Container
Light-blue top (3.2% sodium citrate) and plastic vial
Collection Instructions
Centrifuge and aliquot plasma into a plastic vial. Send refrigerated.
Storage Instructions
Refrigerated (preferred) for 14 days, ambient for 72 hours, or frozen for 30 days.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 14 days |
| Frozen | 30 days |